Efficacy of bazedoxifene on vascular endothelial function in postmenopausal women with osteoporosis

Efficacy of bazedoxifene on vascular endothelial function in postmenopausal women with osteoporosis - Efficacy of bazedoxifene on vascular endothelial function in postmenopausal women with osteoporosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010017

Enrollment

Registered

2013-02-19

Start date

2013-02-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postmenopausal women with osteoporosis

Interventions

Oral bazedoxifene administration (20 mg) once daily Oral risedronate administration (2.5 mg) once daily

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Patients without osteoporosis therapy 2) Postmenopausal women 3) Non-smoker 4) Patients who themselves can voluntarily provide written consent to participate in this study, and can also follow the study protocol

Exclusion criteria

Exclusion criteria: 1) Patients with vain thrombosis 2) Patients with anti-phospholipid antibody syndrome 3) Severe hepatopathy or nephropathy that may affect the evaluation of drug safety 4) Patients who are deemed to be inappropriate by the investigator or sub-investigators

Design outcomes

Primary

Measure	Time frame
Flow mediated dilation (FMD)	—

Secondary

Measure	Time frame
Osteoporosis marker	—

Countries

Japan

Contacts

Public ContactErito Furuse

Nippon Medical School Department of Medicine Division of Cardiology

kubotanomi@yahoo.co.jp03-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026